淘宝店铺小卖家如何做到差异化营销.pptxVIP

Drug Treatment of Metastatic Breast Cancer;Drugs approved for Metastatic Breast Cancer; Paclitaxel 1994 Docetaxel 1996 Trastuzumab 1998 Capecitabine 1998 Capecitabine + Docetaxel 2001 Abraxane 2005 Lapatinib 2006 Ixabepilone 2007 ;Paclitaxel; Paclitaxel 135 mg/m2 3-hour infusion ;TAXOL Efficacy ResultsFull Approval;Docetaxel;DocetaxelAccelerated Approval 1996; Mytomicin 12 mg/m2 Q 6 weeks Vinblastine 6 mg/m2 Q 3 weeks ;TAX304 Efficacy ResultsFull Approval;Trastuzumab;Trastuzumab 4 mg/kg loading dose 2 mg/kg wkly maintenance;Herceptin monotherapy Full Approval;Capecitabine;Capecitabine monotherapy Accelerated Approval;Capecitabine;Docetaxel 100 mg/m2 Q 3 weeks;Capecitabine Efficacy ResultsFull Approval;Overall Survival;Lapatinib; Capecitabine 2500 mg/m2 daily for 14 days ;Lapatinib Efficacy ResultsFull Approval;Efficacy of Combination Therapy:Kaplan-Meier Curves of TTP;Ixabepilone; Capecitabine 1250 mg/m2 BID Days 1 to 14 q 21 days ;Ixabepilone Efficacy ResultsFull Approval;Efficacy of Combination Therapy:Kaplan-Meier Curves of PFS;Ixabepilone; Single-arm Monotherapy Studies (n=126);1st line Metastatic Breast Cancer;Drugs approved in 1st line Metastatic Breast Cancer;Trastuzumab;Chemotherapy Alone;;Herceptin Full Approval Survival All Patients;;Gemcitabine;Paclitaxel 175 mg/m2 Days 1 and 8 q 21 days ;Survival;;ENDPOINTS ;Survival: Basis of cytotoxic drug approval in 1st line MBC;Efficacy Reasons for using Survival as basis of approval in 1st line MBC;Survival as a basis of approval: Examples;Cross-over therapy confounds survival effect: truth or myth?;SUMMARY;See ODAC transcript for Monday June 7, 1999, posted on the FDA website;TTP as the basis of approval: Examples;Progression Free Survival;Problems with PFS;;NDA submissions based on PFS will affect survival data;1、有时候读书是一种巧妙地避开思考的方法。5月-205月-20Sunday, May 31, 20